CALGARY, Alberta--(BUSINESS WIRE)--March 5, 2004--Cellway Ventures Inc. (OTCBB:AGNM - News), a Calgary-based company commencing operations in the biotechnology, pharmaceutical and diagnostics industries, today announced that it has completed a name change to Acrongenomics Inc. to more accurately reflect its emerging business. Concurrently, the Company’s trading symbol will change from “CWYV” to “AGNM”, effective as of today’s date.
The Company recently announced advanced negotiations for the acquisition of all patents and rights to certain diagnostic test products with application to cancer detection.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as “anticipates”, “believes”, “could”, “expects”, “intends”, “may”, “should” and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB and our subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
Contact:
Acrongenomics Inc. W. Scott Lawler, 403-693-8014
Source: Acrongenomics Inc.